ONO Pharma says Taiwan approves Opdivo perioperative regimen for resectable NSCLCPUBT·Aug 19 at 01:05 AMOPHLY-0.78%4528
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatmentsPharmaceutical Technology·Aug 7 at 03:43 AM4528
Ono’s Opdivo wins South Korea approval for resectable NSCLC regimenPUBT·Aug 4 at 02:03 AMOPHLY-0.78%4528
Does Ono’s Expanding Oncology Pipeline and Qinlock Filing Reshape The Bull Case For Ono (TSE:4528)?Simplywall·Jul 9 at 10:54 AMOPHLY-0.78%4528
Ono Pharmaceutical (TSE:4528) Is Down 7.0% After Gastric Cancer Drug ONO-4578 Advances To Phase 3 – Has The Bull Case Changed?Simplywall·Jun 7 at 12:20 AMOPHLY-0.78%4528
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual MeetingMorningStar·Jun 1 at 06:10 PM4528OPHLY-0.78%
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)MorningStar·May 27 at 06:18 PMOPHLY-0.78%4528
Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly ReportSimplywall·May 12 at 05:01 PM4528OPHLY-0.78%
Inhibrx Biosciences shares are trading higher after reports suggesting that the company may see takeover interest from potential suitors including Merck and Ono Pharmaceutical.benzinga_article·Apr 22 at 10:41 AMINBX+4.52%MRK+2.39%
ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With TagrissoTip Ranks·Mar 13 at 11:30 AMOPHLY-0.78%AZN+0.91%
17:00 ETCongruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programsprnewswire·Mar 2 at 04:00 PMXBI+1.44%PBE+1.07%
